Welcome, Guest. Please login or register.
May 28, 2022, 03:36:14 pm

Login with username, password and session length


  • Total Posts: 335
  • Total Topics: 191
  • Online Today: 19
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 4
Total: 4


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Drug Targets Multiple Cancer Types  (Read 1731 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
New Drug Targets Multiple Cancer Types
« on: June 07, 2018, 09:08:09 am »
A new targeted therapy directed against RET mutations, which occur in many types of cancer, demonstrated promising activity in an early clinical trial presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago.

If LOXO-292 continues to do well in larger studies, it could become part of an emerging paradigm of treating cancer based on its genetic characteristics regardless of where it occurs in the body, known as being site or location agnostic.

Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center in New York presented findings from LIBRETTO-001, a global Phase I trial evaluating LOXO-292, Loxo Oncology’s selective inhibitor of the receptor tyrosine kinase RET.

Loxo made headlines at last year’s ASCO meeting with its experimental drug larotrectinib, which is active against all types of cancer with tropomyosin receptor kinase fusions. Larotrectinib received a breakthrough therapy designation and priority review status from the Food and Drug Administration; an approval decision is expected in November.



© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.